{
    "clinical_study": {
        "@rank": "35032", 
        "acronym": "TiCAB", 
        "arm_group": [
            {
                "arm_group_label": "Ticagrelor", 
                "arm_group_type": "Experimental", 
                "description": "Intervention: Drug: Ticagrelor verum + Aspirin placebo"
            }, 
            {
                "arm_group_label": "Aspirin", 
                "arm_group_type": "Active Comparator", 
                "description": "Intervention: Drug: Aspirin verum + Ticagrelor placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This study (TiCAB) is designed as a pivotal efficacy and safety study of Ticagrelor in\n      patients undergoing coronary artery bypass operation. It is designed for the prevention of\n      fatal and non-fatal cardiovascular events in this patient population, a significant, yet\n      unmet medical need."
        }, 
        "brief_title": "Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Coronary Artery Desease,", 
            "Stable Angina,", 
            "Acute Coronary Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": "Acute Coronary Syndrome"
        }, 
        "detailed_description": {
            "textblock": "For stable patients who underwent coronary bypass operation, Aspirin alone currently\n      represents the gold standard of antiplatelet treatment. A few smaller studies using a\n      combination therapy of antiplatelet drugs including Aspirin and Clopidogrel have shown\n      conflicting results. Albeit a number of cardiac surgeons prefer dual antiplatelet therapy\n      with Aspirin and Clopidogrel, Aspirin monotherapy is currently the only guideline\n      recommended therapy after CABG.\n\n      A sub-analysis of PLATO trial comprising more than 1200 ACS patients who were not considered\n      to be appropriately suited for PCI and therefore subjected to CABG operation demonstrated an\n      impressive reduction in mortality in those patients treated with Ticagrelor and Aspirin as\n      compared to Clopidogrel and Aspirin. The labelling of Ticagrelor says that the drug should\n      be paused 7 days prior to surgery. However, a further analysis of this substudy revealed\n      that the largest benefit in the Ticagrelor + Aspirin group as compared to the Clopidogrel +\n      Aspirin group was found in those who stopped study medication at about 48 - 72 hours prior\n      to surgery. There have been pharmacological studies that showed that Ticagrelor may\n      precondition the heart for the trauma of surgery via adenosine mediated effects. Thus, the\n      enormous benefit in the Ticagrelor arm of the PLATO study may be secondary to a pleiotropic\n      action. There was no indication of an accelerated bleeding risk in this study and\n      pharmacological studies document that platelet function should be largely restored of a\n      pause of 48 - 72 hours, such that this duration may allow the optimal preparation for CABG\n      surgery.\n\n      Based on the unmet clinical need regarding optimal antiplatelet therapy after CABG, the\n      results of the PLATO CABG substudy and the observation that Ticagrelor benefits increase\n      with decreasing Aspirin doses, Ticagrelormonotherapy (2x 90mg/day) appears to offer the best\n      balance of safety with anticipated improved efficacy over Aspirin alone. However, there are\n      no data available to support this hypothesis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients 18 years of age or older\n\n          2. Informed, written consent by the patient\n\n          3. Indication for CABG surgery:\n\n               -  coronary three vessel disease, or\n\n               -  left main stenosis, or\n\n               -  two vessel disease with impaired left ventricular function\n\n        Exclusion Criteria:\n\n          1. Indication for oral anticoagulation therapy (i.e. AF) at the time of randomization\n\n          2. Cardiogenic shock, haemodynamic instability\n\n          3. Acute myocardial infarction at presentation (STEMI)\n\n          4. Need for urgent revascularization within 5 days from presentation\n\n          5. Single or two vessel disease with normal LV function (\u2265 50%)\n\n          6. Need for concomitant non-coronary surgery (e.g. valve replacement)\n\n          7. Contraindication for Aspirin or Ticagrelor use (i.e. known allergy)\n\n          8. History of bleeding diathesis within three months prior presentation, significant GI\n             bleed, intra cranial hemorrhage, or liver failure\n\n          9. Patient requires dialysis\n\n         10. Known, clinically important thrombocytopenia (i.e. <100.000/\u00b5l)\n\n         11. Known, clinically important anaemia (i.e. <10mg/dl)\n\n         12. Participation in another investigational drug or device study in the last 30 days\n\n         13. Pregnancy or lactation (for premenopausal women 2 methods of reliable contraception,\n             one of which must be barrier method, are required)\n\n         14. Concomitant oral or intravenous therapy (see examples below) with strong CYP3A\n             inhibitors, CYP3A substrates with narrow therapeutic indices, or strong CYP3A\n             inducers which cannot be stopped for the course of the study\n\n               -  Strong inhibitors: ketoconazole, itraconazole, voriconazole, telithromycin,\n                  clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, indinavir,\n                  atanazavir, over 1 litre daily of grapefruit juice.\n\n               -  Substrates with narrow therapeutic index: cyclosporine, quinidine.\n\n               -  Strong inducers: rifampin/rifampicin, phenytoin, carbamazepine.\n\n         15. Any other condition such as active cancer\n\n         16. Life expectancy less than 12 months that may result in protocol non-compliance or a\n             risk for being lost to follow-up\n\n         17. Indication for major surgery (e.g. cancer treatment, carotid surgery, cerebral\n             surgery, major vascular surgery)\n\n         18. Previous enrolment or randomization of treatment in the present study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "4008", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01755520", 
            "org_study_id": "GE IDE No. D00112", 
            "secondary_id": "2012-003630-16"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ticagrelor", 
                "description": "90mg twice daily dose", 
                "intervention_name": "Ticagrelor", 
                "intervention_type": "Drug", 
                "other_name": "Brilique"
            }, 
            {
                "arm_group_label": "Aspirin", 
                "description": "Aspirin 100mg once daily", 
                "intervention_name": "Aspirin", 
                "intervention_type": "Drug", 
                "other_name": "ASS"
            }, 
            {
                "arm_group_label": "Aspirin", 
                "description": "Placebo", 
                "intervention_name": "Placebo - Ticagrelor", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }, 
            {
                "arm_group_label": "Ticagrelor", 
                "description": "Placebo", 
                "intervention_name": "Placebo - Aspirin", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aspirin", 
                "Ticagrelor"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "CABG,", 
            "CAD,", 
            "antiplatelet drug,", 
            "Ticagrelor,", 
            "Aspirin"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "location": [
            {
                "contact": {
                    "email": "sigrid.sandner@meduniwien.ac.at", 
                    "last_name": "Sigrid Sandner, MD", 
                    "phone": "+43-140400", 
                    "phone_ext": "6969"
                }, 
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria", 
                        "zip": "1090"
                    }, 
                    "name": "Medizinische Universit\u00e4t Wien"
                }, 
                "investigator": {
                    "last_name": "Sigird Sandner, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "schunkert@dhm.mhn.de", 
                    "last_name": "Heribert Schunkert, MD", 
                    "phone": "00498912184073"
                }, 
                "contact_backup": {
                    "email": "kastrati@dhm.mhn.de", 
                    "last_name": "Adnan Kastrati, MD", 
                    "phone": "00498912184578"
                }, 
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany", 
                        "state": "Bavaria", 
                        "zip": "80636"
                    }, 
                    "name": "Deutsches Herzzentrum M\u00fcnchen"
                }, 
                "investigator": {
                    "last_name": "Heribert Schunkert, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rautschbach@ukaachen.de", 
                    "last_name": "R\u00fcdiger Autschbach, MD", 
                    "phone": "+49-241-80", 
                    "phone_ext": "89221"
                }, 
                "facility": {
                    "address": {
                        "city": "Aachen", 
                        "country": "Germany", 
                        "zip": "52074"
                    }, 
                    "name": "Universit\u00e4tsklinikum Aachen"
                }, 
                "investigator": {
                    "last_name": "R\u00fcdiger Autschbach, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "rainer.hambrecht@klinikum-bremen-LdW.de", 
                    "last_name": "Rainer Hambrecht, MD", 
                    "phone": "+49-421-879", 
                    "phone_ext": "1430"
                }, 
                "facility": {
                    "address": {
                        "city": "Bremen", 
                        "country": "Germany", 
                        "zip": "28277"
                    }, 
                    "name": "Gesundheit Nord gGmbH, Klinikum Links der Weser gGmbH"
                }, 
                "investigator": {
                    "last_name": "Rainer Hambrecht, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "1.med.klinik@ctk.de", 
                    "last_name": "J\u00fcrgen Kr\u00fclls-M\u00fcnchen, MD", 
                    "phone": "+49-355-46", 
                    "phone_ext": "2576"
                }, 
                "facility": {
                    "address": {
                        "city": "Cottbus", 
                        "country": "Germany", 
                        "zip": "03048"
                    }, 
                    "name": "Sana Herzzentrum Cottbus GmbH"
                }, 
                "investigator": {
                    "last_name": "J\u00fcrgen Kr\u00fclls-M\u00fcnch, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "malte.kelm@med.uni-duesseldorf.de", 
                    "last_name": "Malte Kelm, MD", 
                    "phone": "+49-211-811", 
                    "phone_ext": "8801"
                }, 
                "facility": {
                    "address": {
                        "city": "D\u00fcsseldorf", 
                        "country": "Germany", 
                        "zip": "40225"
                    }, 
                    "name": "Universit\u00e4tsklinikum D\u00fcsseldorf"
                }, 
                "investigator": {
                    "last_name": "Malte Kelm, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "christian.schlundt@uk-erlangen.de", 
                    "last_name": "Christian Schlundt, MD", 
                    "phone": "+49-9131-853", 
                    "phone_ext": "5000"
                }, 
                "facility": {
                    "address": {
                        "city": "Erlangen", 
                        "country": "Germany", 
                        "zip": "91054"
                    }, 
                    "name": "Universit\u00e4tsklinikum Erlangen"
                }, 
                "investigator": {
                    "last_name": "Christian Schlundt, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "matthias.siepe@universitaets-herzzentrum.de", 
                    "last_name": "Matthias Siepe, MD", 
                    "phone": "+49-761-2702", 
                    "phone_ext": "4010"
                }, 
                "facility": {
                    "address": {
                        "city": "Freiburg", 
                        "country": "Germany", 
                        "zip": "79106"
                    }, 
                    "name": "Universit\u00e4ts-Herzzentrum Freiburg / Bad Krozingen"
                }, 
                "investigator": {
                    "last_name": "Matthias Siepe, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "andreas.boening@chiru.med.uni-giessen.de", 
                    "last_name": "Andreas B\u00f6ning, MD", 
                    "phone": "+49-641-985", 
                    "phone_ext": "44300"
                }, 
                "facility": {
                    "address": {
                        "city": "Gie\u00dfen", 
                        "country": "Germany", 
                        "zip": "35392"
                    }, 
                    "name": "Universit\u00e4tsklinikum Gie\u00dfen"
                }, 
                "investigator": {
                    "last_name": "Andreas B\u00f6ning, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bernd.danner@med.uni-goettingen.de", 
                    "last_name": "Bernd Danner, MD", 
                    "phone": "+49-551-39", 
                    "phone_ext": "6061"
                }, 
                "facility": {
                    "address": {
                        "city": "G\u00f6ttingen", 
                        "country": "Germany", 
                        "zip": "37075"
                    }, 
                    "name": "Universit\u00e4tsmedizin G\u00f6ttingen"
                }, 
                "investigator": {
                    "last_name": "Bernd Danner, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tim.attmann@uksh-kiel.de", 
                    "last_name": "Tim Attmann, MD", 
                    "phone": "+49-431-597", 
                    "phone_ext": "4465"
                }, 
                "facility": {
                    "address": {
                        "city": "Kiel", 
                        "country": "Germany", 
                        "zip": "24105"
                    }, 
                    "name": "Universit\u00e4tsklinikum Schleswig-Holstein, Campus Kiel"
                }, 
                "investigator": {
                    "last_name": "Tim Attmann, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Martin Misfeld, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "zip": "04289"
                    }, 
                    "name": "Herzzentrum Leipzig GmbH"
                }, 
                "investigator": {
                    "last_name": "Martin Misfeld, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "zeymeru@klilu.de", 
                    "last_name": "Uwe Zeymer, MD", 
                    "phone": "+49-621-503", 
                    "phone_ext": "2941"
                }, 
                "facility": {
                    "address": {
                        "city": "Ludwigshafen", 
                        "country": "Germany", 
                        "zip": "67063"
                    }, 
                    "name": "Klinikum Ludwigshafen"
                }, 
                "investigator": {
                    "last_name": "Uwe Zeymer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "michael.reppel@uk-sh.de", 
                    "last_name": "Michael Reppel, MD", 
                    "phone": "+49-451-500", 
                    "phone_ext": "2500"
                }, 
                "facility": {
                    "address": {
                        "city": "L\u00fcbeck", 
                        "country": "Germany", 
                        "zip": "23538"
                    }, 
                    "name": "Universit\u00e4tsklinikum Schleswig-Holstein, Campus L\u00fcbeck"
                }, 
                "investigator": {
                    "last_name": "Michael Reppel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "i.friedrich@bk-trier.de", 
                    "last_name": "Ivar Friedrich, MD", 
                    "phone": "+49-651-208", 
                    "phone_ext": "2751"
                }, 
                "facility": {
                    "address": {
                        "city": "Trier", 
                        "country": "Germany", 
                        "zip": "54292"
                    }, 
                    "name": "Krankenhaus der Barmherzigen Br\u00fcder Trier"
                }, 
                "investigator": {
                    "last_name": "Ivar Friedrich, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Germany"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared With Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation TiCAB- Ticagrelor in CABG", 
        "overall_contact": {
            "email": "schunkert@dhm.mhn.de", 
            "last_name": "Heribert Schunkert, MD", 
            "phone": "00498912184073"
        }, 
        "overall_contact_backup": {
            "email": "gschoemig@dhm.mhn.de", 
            "last_name": "Gisela Schoemig", 
            "phone": "00498912181547"
        }, 
        "overall_official": {
            "affiliation": "Deutsches Herzzentrum Munich Germany", 
            "last_name": "Heribert Schunkert, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Composite of cardiovascular death, myocardial infarction, target vessel revascularization, and stroke", 
            "measure": "MACCE", 
            "safety_issue": "No", 
            "time_frame": "at 12 months after coronary artery bypass surgery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01755520"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cardiovascular death", 
                "safety_issue": "No", 
                "time_frame": "at 12 months after coronary artery bypass surgery"
            }, 
            {
                "description": "Incidence of major bleeding events", 
                "measure": "Major bleeding events", 
                "safety_issue": "Yes", 
                "time_frame": "within 12 months after coronary arerty bypass surgery"
            }, 
            {
                "description": "All cause death", 
                "measure": "All cause death", 
                "safety_issue": "No", 
                "time_frame": "at 12 months after coronary artery bypass surgery"
            }, 
            {
                "measure": "Myocardial Infarction", 
                "safety_issue": "No", 
                "time_frame": "at 12 months after coronary artery bypass surgery"
            }, 
            {
                "measure": "Target Lesion Revascularization", 
                "safety_issue": "No", 
                "time_frame": "at 12 months after coronary artery bypass surgery"
            }, 
            {
                "measure": "Stroke", 
                "safety_issue": "No", 
                "time_frame": "at 12 months after coronary artery bypass surgery"
            }
        ], 
        "source": "Deutsches Herzzentrum Muenchen", 
        "sponsors": {
            "collaborator": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Deutsches Herzzentrum Muenchen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}